Mastodon

Dinox® (Tablets) Instructions for Use

ATC Code

R06AX26 (Fexofenadine)

Active Substance

Fexofenadine (Rec.INN registered by WHO)

Clinical-Pharmacological Group

Histamine H1-receptor blocker. Antiallergic drug

Pharmacotherapeutic Group

Antiallergic agent – H1-histamine receptor blocker

Pharmacological Action

Histamine H1-receptor blocker. Fexofenadine is a pharmacologically active metabolite of terfenadine. It does not have a sedative effect.

The antihistamine effect appears within 1 hour, reaches a maximum in 6 hours, and lasts for 24 hours. No tolerance was observed after 28 days of administration.

It has been established that when taken orally in the dose range from 10 mg to 130 mg, the efficacy of fexofenadine is dose-dependent.

Pharmacokinetics

After oral administration, it is rapidly absorbed from the gastrointestinal tract. Tmax is reached within 1-3 hours. The mean Cmax after a 180 mg dose is approximately 494 ng/ml, and after a 120 mg dose – 427 ng/ml. Plasma protein binding is 60-70%. T1/2 after multiple doses is 11-15 hours. It is excreted in breast milk. 5% of the dose undergoes partial extrahepatic metabolism. It is excreted mainly with bile (80%), 10% is excreted by the kidneys unchanged.

Indications

Relief of symptoms associated with seasonal allergic rhinitis, symptomatic treatment of chronic urticaria.

ICD codes

ICD-10 code Indication
J30.1 Allergic rhinitis due to pollen
L50 Urticaria
ICD-11 code Indication
CA08.00 Allergic rhinitis due to pollen

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

For adults and children over 12 years of age, administer 120 mg to 180 mg orally once daily.

Take the tablet with water. For consistent absorption, administer the dose separately from antacid medications containing aluminum or magnesium hydroxide; maintain a minimum 2-hour interval.

For patients with moderate to severe renal impairment, initiate therapy at the lower end of the dosage range. Exercise caution and consider dose adjustment based on clinical response and tolerability.

The total daily dose must not exceed 180 mg. Do not crush or chew the tablet. The duration of treatment is determined by the physician based on the indication and symptom control.

Adverse Reactions

The following are possible headache, drowsiness, dizziness, fatigue, nausea, lethargy, increased fatigue.

Contraindications

Pregnancy, lactation period, children under 6 years of age, hypersensitivity to fexofenadine.

Use in Pregnancy and Lactation

Fexofenadine is contraindicated for use during pregnancy and during the lactation period (breastfeeding).

Fexofenadine passes into breast milk. If it is necessary to use fexofenadine during lactation, the issue of discontinuing breastfeeding should be decided.

Use in Hepatic Impairment

Use with caution in patients with hepatic insufficiency.

Use in Renal Impairment

Use with caution in patients with renal insufficiency.

Pediatric Use

Use of the drug in children under 6 years of age is not recommended.

Geriatric Use

Use with caution in elderly patients.

Special Precautions

Use with caution in elderly patients, in patients with renal or hepatic insufficiency.

The efficacy and safety of fexofenadine in children under 6 years of age have not been studied.

Effect on the ability to drive vehicles and mechanisms

Based on the pharmacodynamic profile and known side effects, it can be assumed that the effect of fexofenadine on the ability to drive a car and engage in activities requiring increased concentration is unlikely. Objective studies have shown that Fexofenadine does not have a significant effect on CNS functions. Nevertheless, it is recommended to check the individual reaction before driving a car or engaging in other potentially hazardous activities.

Drug Interactions

Fexofenadine is not biotransformed in the liver and therefore does not interact with other drugs undergoing hepatic metabolism.

It has been shown that with the simultaneous use of fexofenadine with erythromycin or ketoconazole, the plasma concentration of fexofenadine increases by 2-3 times, which is apparently associated with an increase in absorption from the gastrointestinal tract and with a reduction in either bile excretion or gastrointestinal secretion. No changes in the QT interval were observed.

When taking antacids containing aluminum or magnesium 15 minutes before taking fexofenadine, a decrease in its bioavailability was observed, most likely due to binding in the gastrointestinal tract. The recommended time interval between taking fexofenadine and antacids containing aluminum or magnesium hydroxide is 2 hours.

Does not interact with omeprazole, with drugs metabolized in the liver.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Marketing Authorization Holder

Dr. Reddy's Laboratories Ltd. (India)

Dosage Form

Bottle OTC Icon Dinox® Film-coated tablets, 120 mg: 10 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets pink, oval, biconvex, with an imprint ” FXF ” on one side, and “120” on the other; on the cross-section – a core of white or almost white color.

1 tab.
Fexofenadine hydrochloride 120 mg

Excipients: cellulose – 261.13 mg, mannitol – 83.34 mg, corn starch – 67.67 mg, croscarmellose sodium – 48 mg, colloidal silicon dioxide – 13.33 mg, magnesium stearate – 7.53 mg.

Film coating composition: opadry pink (hypromellose – 67.995%, titanium dioxide (E171) – 25.055%, macrogol-400 – 6.8%, iron oxide black dye (E172) – 0.036%, brilliant red dye (E129) – 0.114%) – 18 mg.

10 pcs. – PVC/PE/PVDC/aluminum blisters (1) – cardboard packs.

Marketing Authorization Holder

Dr. Reddy's Laboratories Ltd. (India)

Dosage Form

Bottle OTC Icon Dinox® Film-coated tablets, 30 mg: 10 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets 1 tab.
Fexofenadine hydrochloride 30 mg

10 pcs. – contour cell packs (1) – cardboard packs.

Marketing Authorization Holder

Dr. Reddy's Laboratories Ltd. (India)

Dosage Form

Bottle OTC Icon Dinox® Film-coated tablets, 60 mg: 10 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets 1 tab.
Fexofenadine hydrochloride 60 mg

10 pcs. – contour cell packs (1) – cardboard packs.

Marketing Authorization Holder

Dr. Reddy's Laboratories Ltd. (India)

Dosage Form

Bottle OTC Icon Dinox® Film-coated tablets, 180 mg: 10 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets 1 tab.
Fexofenadine hydrochloride 180 mg

10 pcs. – contour cell packs (1) – cardboard packs.

TABLE OF CONTENTS